The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopy system, surgical microscopes, endoscope reprocessors, operating rooms, repair and maintenance services. It operates through: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others segments. Olympus Corporation manufactures and sells precision machineries and instruments worldwide. was founded in 1978 and is headquartered in Burlington, Massachusetts. The company was formerly known as Brooks Automation, Inc. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage equipment for sample preparation and handling consumables and instruments that help customers in managing samples throughout their research discovery and development workflows. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. SummaryĪzenta beats Olympus on 8 of the 9 factors compared between the two stocks. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. 1.7% of Azenta shares are owned by insiders. Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).99.5% of Azenta shares are owned by institutional investors. Current multiples include: - Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM) - Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. One of the most widely used quantitative methods is the market multiples method. In reality, business valuation is often a combination of these different approaches. Many methods can be used to value a company. The (current) company valuation of Endo International Plc is therefore way below its valuation average over the last five years. The P/Earnings NTM ratio of Endo International Plc is significantly lower than its historical 5-year average: 2.5. The company valuation of Endo International Plc according to these metrics is way below the market valuation of its sector. The P/Earnings NTM ratio of Endo International Plc is significantly lower than the average of its sector (Pharmaceuticals): 6.39. The company valuation of Endo International Plc according to these metrics is way below the market valuation of its peer group. The P/Earnings NTM ratio of Endo International Plc is significantly lower than the median of its peer group: around 15.00. A company with a high P/Earnings NTM is considered to be overvalued a company with a low P/Earnings NTM is considered to be undervalued. This multiple is used to compare a company's market value with its earnings. P/E relates the current share price with the market expectations in terms of Earnings Per Share. The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). Market multiple valuation of Endo International Plc ( ENDP | IRL)
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |